Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults with Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

Trial Identifier: 8591-013
Sponsor: MSD
Start Date: March 2021
Primary Completion Date: January 2025
Study Completion Date: January 2025
Condition: Human Immunodeficiency Virus (HIV)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
France, Haute-Garonne Toulouse, Haute-Garonne, France, 31059
France, Herault Montpellier Cedex 5, Herault, France, 34295
France, Ile-de-France Paris, Ile-de-France, France, 75013
France, Loire-Atlantique Nantes, Loire-Atlantique, France, 44093
France, Loiret Orleans, Loiret, France, 45100
France, Paris Paris, France, 75010
France, Paris Paris, France, 75012
France, Seine-Saint-Denis Bobigny, Seine-Saint-Denis, France, 93000
Switzerland, Aargau Zuerich, Aargau, Switzerland, 8091
Switzerland, Basel-Stadt Basel, Basel-Stadt, Switzerland, 4031
Switzerland, Berne Bern, Berne, Switzerland, 3010
Switzerland, Geneve Geneva, Geneve, Switzerland, 1211
Switzerland, Vaud Lausanne, Vaud, Switzerland, 1011
United States, AZ Phoenix, AZ, United States, 85015
United States, CA Los Angeles, CA, United States, 90069
United States, FL Fort Pierce, FL, United States, 34982
United States, FL West Palm Beach, FL, United States, 33407
United States, GA Decatur, GA, United States, 30033
United States, GA Savannah, GA, United States, 31410
United States, MO Kansas City, MO, United States, 64111
United States, TX Bellaire, TX, United States, 77401
United States, TX Fort Worth, TX, United States, 76104
United States, TX Longview, TX, United States, 75605